Prevention of Breast Cancer-related Lymphedma With Tacrolimus
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Breast cancer-related lymphedema is one of the most common and feared consequences of breast
cancer treatment. Tacrolimus ointment may prevent lymphedema by inhibition of CD4+T cells.